Article

Evaluation of the potential drug interaction of melatonin and warfarin: A case series

Authors:
To read the full-text of this research, you can request a copy directly from the authors.

Abstract

Melatonin has the potential to interact with warfarin for many reasons. According to the Micromedex drug interaction database, melatonin has been associated with bleeding complications and reduced prothrombin time (PT) in four case reports of patients who received both melatonin and warfarin. However, there is no primary literature that supports this finding. The objective of this case series is to evaluate potential drug interactions between melatonin and warfarin. Ten adult patients, who admitted to Massachusetts General Hospital (MGH) (Boston, MA) between April 2011 and April 2012 and were treated with melatonin and warfarin concurrently, were evaluated. MGH is a 950-bed teaching hospital. Those 10 patients had changes in INR and PT. They are selected because they were not on any other medications that have major interactions with warfarin, did not receive other anticoagulants, chemotherapy, as needed or 1 dose of melatonin during their hospital stay. The Drug Interaction Probability Scale (DIPS) was used to evaluate the potential drug interaction, and the following outcomes were recorded for each patient: bleeding events, INR, PT, albumin, and LFTs. The 10 patients were 54 years old or older and the duration of concurrent administration of both medications ranged from 2 to 10 days. Melatonin dose was stable in all 10 patients while warfarin dose had changed (increased/ decreased) in some patients. Both INR and PT increased in most patients during concurrent administration of melatonin with warfarin and no bleeding events have been noted. By calculating DIPS score for each patient, we found that 6 patients experienced possible drug interaction, 2 had probable drug interaction, and 2 had doubtful drug interaction. LFTs and albumin were normal in most patients. In conclusion, concurrent use of melatonin and warfarin may result in INR and PT changes and affects coagulation activity. Monitoring INR and PT regularly is suggested when both medications are administered concurrently. � 2016, Zhengzhou University. All rights reserved.

No full-text available

Request Full-text Paper PDF

To read the full-text of this research,
you can request a copy directly from the authors.

... The authors concluded that the combined use of warfarin and melatonin leads to a change in PT and INR and influences the coagulation activity. They suggested that regular monitoring of PT and INR is recommended for those concurrently receiving both drugs [82]. ...
Article
Severe COVID-19 is associated with the dynamic changes in coagulation parameters. Coagulopathy is considered as a major extra-pulmonary risk factor for severity and mortality of COVID-19; patients with elevated levels of coagulation biomarkers have poorer in-hospital outcomes. Oxidative stress, alterations in the activity of cytochrome P450 enzymes, development of the cytokine storm and inflammation, endothelial dysfunction, angiotensin-converting enzyme 2 (ACE2) enzyme malfunction and renin–angiotensin system (RAS) imbalance are among other mechanisms suggested to be involved in the coagulopathy induced by severe acute respiratory syndrome coronavirus (SARS-CoV-2). The activity and function of coagulation factors are reported to have a circadian component. Melatonin, a multipotential neurohormone secreted by the pineal gland exclusively at night, regulates the cytokine system and the coagulation cascade in infections such as those caused by coronaviruses. Herein, we review the mechanisms and beneficial effects of melatonin against coagulopathy induced by SARS-CoV-2 infection.
... Beyond such contrasting findings, a more pertinent problem faced by passengers with cardiovascular conditions is the time dosing of their medications, especially with abrupt changes in time zones, meals, and wakefulness in transcontinental flights. 22 Certain nonprescription sleep supplements (such as melatonin) consumed by passengers for sleep adjustment have also been observed to interfere or interact with cardiovascular medications, 28,29 and dose titration of the implicated cardiac medications may be required to maintain optimal effects. Some (such as temazepam, zaleplon, etc) may also have direct effects on the cardiovascular system, 30 and discontinuation or avoidance of such pharmacological sleep aids should be strongly advised. ...
Article
The exponential growth of commercial flights has resulted in a sharp rise of air travellers over the last 2 decades, including passengers with a wide range of cardiovascular conditions. Notwithstanding the ongoing COVID-19 pandemic that had set back the aviation industry for the next 1 to 2 years, air travel is expected to rebound fully by 2023-2024. Guidelines and evidence-based recommendations for safe air travel in this group vary, and physicians often encounter situations where opinions and assessments on fitness for flights are sought. This article aims to provide an overview of the stressors of commercial passenger flights with an impact on cardiovascular health for the general cardiologist and family practitioner, when assessing the suitability of such patients for flying fitness.
... Melatonin, a signaling molecule for circadian rhythms, plays an important role in many biological processes (Dahm et al. 2006, Kostovski et al. 2011. It was suggested that endogenous melatonin may also produce antithrombotic, antioxidant and antiinflammatory activity (Carrillo-Vico et al. 2005, Claustrat et al. 2005, Dahm et al. 2006, Ashy and Shroff 2016. Depend on its wide effects, melatonin could be expected to regulate hemostatic events and the effects of melatonin on hemostasis are relatively poorly studied (Kostovski et al. 2011). ...
ResearchGate has not been able to resolve any references for this publication.